Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2018

View Archived Issues

Local factors greatly affect myelination state

Pharmacokinetic data of anti-CD22 TTC BAY-1862864 suggest good stability and biodistribution

[225Ac]FPI-1434 demonstrates theranostic potential in multiple preclinical models of human cancer

Strong tumor-targeting in mice treated with the [99mTc]-labeled CCK2R-antagonist DGA1

Hisamitsu begins phase II trial in Japan with HP-5070 for primary local hyperhidrosis

ConsortiaTx signs license for foundational intellectual property related to CTX-944

Chromosome microarray reveals a chromosome 17q duplication and deletion in a patient

Weill Cornell Medicine describes improved CXCR4 ligands for PET imaging

Chengdu Euthare Therapeutics identifies CDK4 and CDK6 inhibitors

Raf kinase regulates mast cell activation, allergic response

Ocean University of China patents new antivirals

Japanese researchers present ROR-gammaT antagonists

CureVac begins phase I trial with prophylactic mRNA rabies vaccine CV-7202

Bayer synthesizes new CDK9 inhibitors

FDA approves Afluria Quadrivalent for use in individuals age 6 months and older

Plinabulin + Neulasta reduce grade 3/4 CIN and bone pain in phase II trial

Probiodrug discovers QPCT inhibitors

ADCT-602 studied in phase I/II trial for recurrent or refractory B-cell ALL

Darolutamide significantly extends metastasis-free survival in nonmetastatic CRPC

Celgene reports PFS improvement with Revlimid in smoldering multiple myeloma

Zymeworks and Leo Pharma enter licensing and research collaboration for bispecific antibodies

FDA agrees with Scynexis on phase III plans for ibrexafungerp in VVC

Enanta begins phase IIa study of EDP-938 to treat RSV infection

First positive phase III data for PIK3CA inhibitor alpelisib in breast cancer

Xortx's pre-IND meeting with FDA identifies accelerated clinical development plan for XRx-008

Santhera begins phase Ib/IIa study of POL-6014 in cystic fibrosis

Phase I study indicates lower effective dose with [18F]PSMA-11 than other PSMA ligands

Biogen discontinues development of vixotrigine for painful lumbosacral radiculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...